Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Supernus Pharmaceuticals (SUPN) reported $174.16 million in revenue for Q4 2024, a 6% year-over-year increase, with an EPS of $0.75 compared to $0.02 a year ago, indicating strong financial performance [1] - The revenue exceeded the Zacks Consensus Estimate of $155.25 million by 12.18%, and the EPS surpassed the consensus estimate of $0.52 by 44.23% [1] Revenue Breakdown - Net product sales for Trokendi XR were $14.80 million, exceeding the average estimate of $9.34 million, but showing a year-over-year decline of 24.5% [4] - Oxtellar XR generated $13.20 million, slightly below the estimated $13.21 million, reflecting a significant year-over-year decrease of 57.4% [4] - Qelbree sales reached $74.40 million, surpassing the estimate of $65.08 million, marking a substantial year-over-year increase of 60.3% [4] - Total net product sales amounted to $166.40 million, exceeding the average estimate of $149.84 million, with a year-over-year growth of 6.7% [4] - Royalty revenues were reported at $7.76 million, above the estimated $5.40 million, but down 6.4% from the previous year [4] - GOCOVRI sales were $36.90 million, slightly above the estimate of $36.11 million, with a year-over-year increase of 15.3% [4] - Other net product sales totaled $7 million, below the estimate of $7.83 million, reflecting a year-over-year decline of 15.7% [4] - APOKYN generated $20.10 million, exceeding the estimate of $17.50 million, with a year-over-year increase of 7.5% [4] Stock Performance - Supernus shares have returned -17.1% over the past month, compared to a -1.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), suggesting potential for outperformance in the near term [3]